Provention Bio Inc (PRVB) Stock
PRVB is no longer traded. Provention Bio was acquired by Sanofi (SNY) on April 27, 2023.
Each PRVB share was exchanged for $25.00 in cash. Prices on this page are historical; the last trade was April 26, 2023 at $24.98.
See Sanofi (SNY) stock →Provention Bio stock price history
PRVB final trading statistics
- Final close
- $24.98
- Final trading day
- Apr 26, 2023
- Market cap at delisting
- $2.28B
- Shares outstanding
- 91.10M
- Final 52-week range
- $3.19 – $25.00
- Avg. volume (final 3 mo.)
- 2,670,691
- All-time high (split-adj.)
- $24.98 · Apr 2023
- All-time low (split-adj.)
- $1.73 · Dec 2018
- Return since IPO
- +419.3%
- Beta
- 2.46
- Book value / share
- $1.39
- Price / book
- 17.97
Provention Bio annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $12.89M | -$113.6M | -$1.60 |
| FY2021 | $1.40M | -$114.4M | -$1.82 |
| FY2020 | $0.00 | -$98.6M | -$1.85 |
| FY2019 | $0.00 | -$42.2M | -$1.07 |
| FY2018 | $0.00 | -$26.5M | -$0.46 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Provention Bio Inc
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio stock FAQ
What happened to Provention Bio stock?
Provention Bio was acquired by Sanofi (SNY) on April 27, 2023. Shareholders received $25.00 in cash for each share. PRVB stock stopped trading on the Nasdaq, with a final close of $24.98 on April 26, 2023.
What did Provention Bio shareholders receive?
Each PRVB share was converted into $25.00 in cash. The deal was valued at about $2.9 billion.
Is PRVB stock still trading?
No. PRVB was delisted from the Nasdaq on April 27, 2023 and no longer trades on a U.S. exchange.
What was the last price of PRVB stock?
PRVB closed at $24.98 on its final trading day, April 26, 2023, for a market value of about $2.28B.
What were Provention Bio's revenue and earnings in its last full fiscal year?
Provention Bio reported revenue of $12.89M and net income of -$113.6M in fiscal 2022, its last full year as a public company.
When did Provention Bio go public?
Provention Bio Inc stock began trading on July 24, 2018.